CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.
^"Der reichste Ebener aller Zeiten". Handelszeitung (in German). 2021-12-14. Retrieved 2022-05-10.
^Kanstein, Fraiser (2022-08-02). "After delay, CSL's $11.7B deal for Vifor poised to close next week". Fiercepharma. Retrieved 2022-12-29.
^Redrup, Yolanda (2022-02-18). "Vifor results show strength as CSL tender period nears end". Australian Financial Review. Retrieved 2022-02-28.
CSLVifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered...
CSL rebranded all of its divisions to start with the CSL name. Therefore, the divisions became CSL Behring, CSL Plasma, CSL Seqirus, and CSLVifor. CSL...
CSL's $11.7B deal for Vifor poised to close next week". Fierce Pharma. Retrieved 11 October 2023. Official website CSL Limited official website CSL Plasma...
Bachem was added to the index, replacing Vifor Pharma , because after sell of Vifor Pharma to the Australian CSL the free float dropped to 1.6% which is...
Deutschland Swedish Orphan Biovitrum GmbH Takeda Deutschland UCB (company) GmbH Vifor Deutschland GmbH ViiV Healthcare GmbH In 2010, the vfa and the BPI were...
Global Information
CHF 1.75 billion (2021)[3]